Efficacy data of 
ICLUSIG (ponatinib) in Ph+ ALL

Explore ICLUSIG efficacy in Philadelphia chromosome-positive acute lymphoblastic leukemia

Pivotal efficacy data across two trials covering newly diagnosed Ph+ ALL and resistant/T315I-positive Ph+ ALL1-3

ICLUSIG efficacy in Ph+ ALL is supported by two pivotal trials. PhALLCON, the first head-to-head phase 3 clinical trial vs another TKI in adults with newly diagnosed Ph+ ALL, established ICLUSIG + chemotherapy as the only FDA-approved regimen with data showing superior efficacy and comparable safety vs imatinib + chemotherapy.1,2 PACE provides efficacy data for ICLUSIG monotherapy in patients with Ph+ ALL whose disease is resistant or intolerant to a prior TKI or who have the T315I mutation.1

PhALLCON trial efficacy data of ICLUSIG
in newly diagnosed Ph+ ALL

PACE trial efficacy data of ICLUSIG in Ph+ ALL

Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; TKI=tyrosine kinase inhibitor

View ICLUSIG safety profile in Ph+ ALL

View ICLUSIG optimized dosing in newly diagnosed Ph+ ALL

Ph+ ALL Patient Profiles

""

Ph+ ALL Dosing Guide

""

Ph+ ALL resources and support

""